Duke Team Validates Placental Blood As Viable Source For Bone Marrow Transplantation

July 18, 1996

DURHAM, N.C. -- Doctors at Duke University Medical Center and the New York Blood Center have reported the first scientific validation that placental blood from unrelated, newborn donors can be used in place of adult bone marrow for pediatric bone marrow transplants.

The Duke team, led by Dr. Joanne Kurtzberg, was the first in the world to perform unrelated placental blood transplants in children and has performed 54 of the world's 180 such transplants in the last 35 months.

The researchers said this technique will enable children who lack suitably matched relatives or unrelated adult donors to receive life-saving transplants using stored placental or "umbilical cord" blood, a substance normally discarded after birth. Bone marrow transplants are performed to treat patients with leukemia and other blood diseases, certain cancers and inherited metabolic diseases.

In an article in the July 18 New England Journal of Medicine, researchers provide a scientific analysis of their first 25 pediatric transplant patients at Duke. The analysis showed that 16 patients survived at least the first 100 days after the transplant and 23 patients accepted their newly transplanted cells, a crucial stage in recovery known as engrafting.

To date, 28 of the 54 Duke patients are alive and doing well, Kurtzberg said. Of the 25 patients described in the article, 12 are alive and well eight to 34 months later.

Most important, say the scientists, their research adds weight to the theory that T-cells in cord blood are less mature than those in adult bone marrow, so that donor and recipient do not have to be a perfect genetic match.

"Hundreds of children die each year awaiting a genetically matched adult donor," said Kurtzberg, whose decades of research have been funded, in part, by the Leukemia Society of America and the American Cancer Society. "The significance of validating cord blood as a viable source for transplantation is that children who don't have time to find a donor, or whose genetic makeup is so complex that no donor exists in the national registry, will now have an alternate donor source for transplantation." Patients need new bone marrow to replace their own, which is destroyed as a side effect of the high doses of chemotherapy and radiation used to eradicate their diseases.

All of the Duke patients received their cord blood from a placental blood bank established in 1991 by Dr. Pablo Rubinstein at the New York Blood Center and funded by the National Heart, Lung and Blood Institute. The center now has more than 6,000 units of stored placental blood from which patients can search for a completely or partially compatible match.

"This is the first major study of transplantation of cord blood from unrelated donors in a single institution," said Dr. Claude Lenfant, director of the National Heart, Lung and Blood Institute. "Although more research is needed to confirm its findings, it shows the potential of this therapy for treating children with cancer and genetic disorders."

Finding a perfect genetic match from a traditional adult donor is difficult because the donor and patient must have six genetically-matched blood proteins -- called human leukocyte antigens. Without such a match, the patient's remaining blood-forming cells can attack and expel the donor's blood cells, an event known as rejection. A mismatched bone marrow transplant also increases the risk of graft-versus-host disease, Kurtzberg said. The chances of two unrelated individuals matching range from one in 100 to one in 2 million, depending on the patient's genetic makeup.

"Umbilical cord blood is very rich in the same blood components that are present in adult marrow, like stem cells and T-cells, but with the added benefit of being immature, so they more easily adapt to their new surroundings and thus are less likely to cause graft-versus-host disease," Kurtzberg said. Cord blood is also less likely to be contaminated with viruses that could cause serious infections in transplants recipients, whose immune systems are weakened by high-dose treatments.

The Duke team found that patients receiving cord blood needed only a partial match in order to be successful. Of the 25 patients, only one was a full genetic match. The others matched either one, two or three of their donor's six blood antigens.

Until the cord blood experiments, the only donor sources of bone marrow were family members or unrelated donors listed in the National Marrow Donor Program (NMDP), a databank that contains more than 2 million potential volunteer donors. But even family members are rarely a full genetic match, and patients with unusual genetic backgrounds -- such as American Indians or racially mixed individuals -- often cannot find a suitable donor through the NMDP. Less than 20 percent of people in the registry are minorities or have mixed ancestry. Moreover, searching the registry takes an average of four to six months -- too long for many patients with aggressive or recurrent cancers.

In addition to its medical advantages, cord blood offers several practical benefits.
First, the stored units of blood already have undergone the sophisticated and lengthy tissue typing process and infectious-disease testing, so blood is available within days rather than months. And because umbilical cord blood is considered discarded material from the baby's delivery, there is no risk to the baby or mother when it is collected.

Cord blood also saves the expense of harvesting bone marrow -- which costs between $10,000 and $20,000 when using a living, unrelated donor -- and avoids subjecting the donor to the discomfort and risk of harvesting bone marrow. Finally, cord blood is rich in stem cells, and thus the procedure requires only two to 10 ounces versus approximately 50 ounces or three pints of adult marrow.
-end-


Duke University

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.